Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715145 | 0.92 | KDM4E (0.44) | FABP3KDM4EMEN1GLACASP1 | |
| SCHEMBL4713050 | 0.86 | LMNA (0.44) | KDM4EMEN1KMT2ACYP2C9PLA2G7 | |
| SCHEMBL6368271 | 0.84 | CYP2C9 (0.38) | FABP3KDM4EFABP4PTGDR2CYP2C9 | |
| SCHEMBL3537123 | 0.84 | PLA2G7 (0.52) | FABP3KDM4EMEN1GLACASP1 | |
| SCHEMBL4713329 | 0.83 | PLA2G7 (0.40) | KDM4EMEN1GLACASP1CASP7 | |
| SCHEMBL4712991 | 0.83 | PLA2G7 (0.40) | KDM4EMEN1GLACASP1CASP7 | |
| SCHEMBL4715470 | 0.83 | KDM4E (0.44) | KDM4EMEN1GLACASP1CASP7 | |
| SCHEMBL4714043 | 0.81 | FABP3 (0.45) | FABP3KDM4EMEN1GLACASP1 | |
| SCHEMBL4712441 | 0.81 | KMT2A (0.48) | FABP3KDM4EMEN1GLACASP1 | |
| SCHEMBL4717562 | 0.81 | PLA2G7 (0.49) | KDM4EMEN1GLACASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651403-B1 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | GLAXO GROUP LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-2977452-A2 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2155225-B1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-9029383-B2 | Methods of treatment of skin ulcers | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-8962633-B2 | Methods of treatment and prevention of metabolic bone diseases and disorders | THOMAS JEFFERSON UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2651403-A2 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | Glaxo Group Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-20130267544-A1 | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases | GLAXO GROUP LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130150379-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2008141176-A1 | METHODS OF TREATMENT OF SKIN ULCERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280829-A1 | METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
| US-20040058941-A1 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1337517-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002030911-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280829-A1 | METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS | ENPP2, PLA2G12A, PLA2G12B | FABP3 525/4885KDM4E 3511/4885MEN1 1658/4885 |
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, PLA2G1B, PLA2G2A | FABP3 456/4885KDM4E 4297/4885MEN1 3919/4885 |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | PLA2G12A, PLA2G3, PLA2G4A | FABP3 297/4885KDM4E 4598/4885MEN1 4824/4885 |
| US-20130150379-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, PLA2G1B, PLA2G2A | FABP3 373/4885KDM4E 4479/4885MEN1 4175/4885 |
| US-20130267544-A1 | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases | PLA2G4A, PLA2G1B, PLA2G4B | FABP3 455/4885KDM4E 3715/4885MEN1 3405/4885 |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, LPAR1, PLA2G1B | FABP3 481/4885KDM4E 4411/4885MEN1 4377/4885 |
| US-20040058941-A1 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | TYMP, LPL, PLAT | FABP3 897/4885KDM4E 2919/4885MEN1 3236/4885 |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | FABP3 568/4885KDM4E 3484/4885MEN1 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.